[Clinical efficacy and safety of ulinastatin plus octreotide for patients with severe acute pancreatitis].

OBJECTIVE:

To explore the clinical efficacy and safety of ulinastatin plus octreotide for patients with severe acute pancreatitis (SAP).

METHODS:

During January 2011 to January 2014 at our hospital, 120 SAP patients were randomly divided into control and observation groups (n = 60 each). The control group received an injection of octreotide injection while the observation group had a combination of ulinastatin and octreotide. After treatment, clinical efficiency, serum indicators and their improvements and complications were compared for two groups.

RESULTS:

The overall efficiency of observation group was significantly higher than that of control group (83.3% vs 65.0%, P < 0.05). And abdominal pain relief time, decompression time, surgical intervention rate, length of stay and mortality rate of observation group (1.9 ± 0.9 d, 6.3 ± 2.2 d, 1.7%, 11.8 ± 0.5 d, 5%) were significantly lower than those of control group (3.6 ± 0.7 d, 10.4 ± 3.1 d, 8.3%, 23.7 ± 2.1 d, 15.0%) (P < 0.05). After treatment, the levels of blood amylase, white blood cell (WBC), C-reactive protein (CRP) and interleukin 6 (IL-6) of observation group (107.2 ± 9.1 U/L, 6.2 ± 1.0 × 10(9)/L, 7.3 ± 3.4 mg/L, 28.3 ± 4.3 pg/ml) were significantly lower than those of control group (430.8 ± 20.2) U/L, (11.2 ± 1.2) × 10(9)/L, (16.3 ± 5.2) mg/L, (45.3 ± 5.9) ng/L, (P < 0.05). And the incidences of such complications as acute respiratory distress syndrome (ARDS), acute renal failure and shock of observation group (10.0%, 5.0%, 13.3%) were significantly lower than those of control group (36.7%, 21.7%, 33.3%) (P < 0.05).

CONCLUSION:

Ulinastatin plus octreotide can significantly improve the serum and clinical parameters and reduce the incidence of complications in SAP patients. And it is worthy of wider popularization.